JAN 15 2004 B

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re the Application of

Stevan D. Tofovic, et al.

Serial No.: 10/633,410

Filed: August 4, 2003

For: AMINISTRATION OF ESTRADIOL

METABOLITES FOR INHIBITION OF

DRUG-INDUCED NEPHROTOXICITY

Group Art Unit: 1614

Examiner:

INFORMATION DISCLOSURE STATEMENT
 UNDER 37 C.F.R. § 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure as defined in 37 C.F.R. § 1.56 enclosed herewith for the Examiner's consideration is a copy of the publications listed on the attached Form PTO-1449. This statement is made pursuant to 37 C.F.R. § 1.97(b) since a first Office Action on the merits has not been mailed in the above-identified application.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that:

(1) additional information material to the examination of this application does not exist; (2) the information, protocols, results and the like reported by third parties are accurate or

enabling; or (3) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Mary-Elizabeth Buckles

REED SMITH LLP

Attorneys for Applicant

Mary-Elizabeth Buckles 1301 K Street, N.W. Suite 1100-East Tower Washington, D.C. 20005 (202) 414-9267

Filed: January 15, 2004

ATTY. DOCKET NO. FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE SERIAL NO. PATENT AND TRADEMARK OFFICE 10/633,410 (MODIFIED) **INFORMATION DISCLOSURE APPLICANT** STATEMENT BY APPLICANT Stevan D. Tofovic, et al. (Use several sheets if necessary) FILING DATE GROUP (37 CFR 1.96(b)) August 4, 2003 1614 **U.S. PATENT DOCUMENTS** EXAMINER ISSUE **FILING DATE** INTIAL **PATENT NUMBER** DATE **PATENTEE** CLASS **SUBCLASS** APPROPRIATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION DOCUMENT NUMBER PUBLIC COUNTRY OR PATENT OFFICE CLASS SUBCLASS TRANSLATIO NO YES

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

1	Lindner, A. B., et al., <u>N. Engl. J. Med.</u> 290:697 (1974)
2	United States Renal Data System:1993 Annual Data Report, MD. U.S. Department of Health and Human Services, Public Health Services, National Institutes of Health, p. xvi (1993)
3	Neugarten, J., et al., <u>J. Am. Soc. Nephrol.</u> <u>11</u> :319 (2000)
4	Silbiger, S. R., et al., <u>Am. J. Kid. Disease</u> <u>25</u> :515 (1995)
 5	Manson, J. E., et al., <u>N. Engl. J. Med.</u> 345: 34 (2001)
6	Braunstein, G. D., <u>New England J. Med.</u> <u>328</u> :490 (1993)
7	Ball, P., et al., <u>Am. J. Obstet. &amp; Gyn.</u> <u>163</u> : 2163 (1990)
8	Lowry, O. H., et al., <u>J. Biol. Chem.</u> <u>193</u> : 265 (1951)
9	Grond, J., et al., <u>Contributions to Nephrology</u> 60:83 (1988)
10	Reckelhoff, J.F., et al., Clin. & Exp. Pharm. & Phys. 26:127 (1999)

**EXAMINER:** Initial citati n c nsid r d. Draw line thr ugh citati n if n t in c nf rmance and n t considered. Include copy of this form with next communication to applicant.

 $\mathcal{C}_{i}$ 

JAN 1 5 2004